CoChat

Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Open access
Adamson, Carly, Kondo, Toru, Jhund, Pardeep S, de Boer, Rudolf A, Cabrera Honorio, Jose Walter, Claggett, Brian, Desai, Akshay S, Alcocer Gamba, Marco Antonio, Al Habeeb, Waleed, Hernandez, Adrian F, Inzucchi, Silvio E, Kosiborod, Mikhail N, Lam, Carolyn S P, Langkilde, Anna Maria, Lindholm, Daniel, Bachus, Erasmus, Litwin, Sheldon E, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J, Vaduganathan, Muthiah, Nguyen Vinh, Pham, Wilderäng, Ulrica, Solomon, Scott D, McMurray, John J V · 2022 · European Heart Journal
Cited by 154

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Aims: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to body mass index (BMI) among patients in the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure trial. Methods and results: Body mass index was analysed by World Health Organization (WHO) categories and as a continuous variable using restricted cubic splines. Body mass index ranged from 15.2 to 50 kg/m2 with a mean value of 29.8 (standard deviation ± 6.1) kg/m2. The proportions, by WHO category, were: normal weight 1343 (21.5%); overweight 2073 (33.1%); Class I obesity 1574 (25.2%); Class II obesity 798 (12.8%); and Class III obesity 415 (6.6%). Compared with placebo, dapagliflozin reduced the risk of the primary outcome to a similar extent across these categories: hazard ratio (95% confidence interval): 0.89 (0.69–1.15), 0.87 (0.70–1.08), 0.74 (0.58–0.93), 0.78 (0.57–1.08), and 0.72 (0.47–1.08), respectively (P-interaction = 0.82). The placebo-corrected change in Kansas City Cardiomyopathy Questionnaire total symptom score with dapagliflozin at 8 months was: 0.9 (−1.1, 2.8), 2.5 (0.8, 4.1), 1.9 (−0.1, 3.8), 2.7 (−0.5, 5.8), and 8.6 (4.0, 13.2) points, respectively (P-interaction = 0.03). The placebo-corrected change in weight at 12 months was: –0.88 (−1.28, –0.47), –0.65 (−1.04, –0.26), –1.42 (−1.89, –0.94), –1.17 (−1.94, –0.40), and –2.50 (−4.4, –0.64) kg (P-interaction = 0.002). Conclusions: Obesity is common in patients with HFpEF and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac481

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 17

  1. Aune, 2016, Body mass index, abdominal fatness, and heart failure incidence and mortality, Circulation, 133, 639, 10.1161/CIRCULATIONAHA.115.016801 · DOI · Paper page
  2. Ho, 2016, Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Subtypes, Circ Heart Fail, 9, e003116, 10.1161/CIRCHEARTFAILURE.115.003116 · DOI · Paper page
  3. Pandey, 2018, Physical activity, fitness, and obesity in heart failure with preserved ejection fraction, JACC Heart Fail, 6, 975, 10.1016/j.jchf.2018.09.006 · DOI · Paper page
  4. Kitzman, 2017, Obese heart failure with preserved ejection fraction phenotype, Circulation, 136, 20, 10.1161/CIRCULATIONAHA.117.028365 · DOI
  5. Joyce, 2016, Prevalence, profile and prognosis of severe obesity in contemporary hospitalized heart failure trial populations, JACC Heart Fail, 4, 923, 10.1016/j.jchf.2016.09.013 · DOI · Paper page
  6. Packer, 2018, Derangements in adrenergic–adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction, Eur J Heart Fail, 20, 873, 10.1002/ejhf.1167 · DOI · Paper page
  7. Neeland, 2013, Relation of regional fat distribution to left ventricular structure and function, Circ Cardiovasc Imaging, 6, 800, 10.1161/CIRCIMAGING.113.000532 · DOI · Paper page
  8. Rao, 2020, Regional adiposity and heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 1540, 10.1002/ejhf.1956 · DOI · Paper page
  9. Cai, 2017, Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis, J Diabetes Investig, 8, 510, 10.1111/jdi.12625 · DOI · Paper page
  10. Zaccardi, 2016, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis, Diabetes Obes Metab, 18, 783, 10.1111/dom.12670 · DOI · Paper page
  11. Solomon, 2021, Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial, Eur J Heart Fail, 23, 1217, 10.1002/ejhf.2249 · DOI · Paper page
  12. Solomon, 2022, Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction, JACC Heart Fail, 10, 184, 10.1016/j.jchf.2021.11.006 · DOI · Paper page
  13. Lavie, 2016, Update on obesity and obesity paradox in heart failure, Prog Cardiovasc Dis, 58, 393, 10.1016/j.pcad.2015.12.003 · DOI · Paper page
  14. Adamson, 2021, Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index, Eur J Heart Fail, 23, 1662, 10.1002/ejhf.2308 · DOI · Paper page
  15. Miller, 2020, Impact of obesity on volume Status in patients with ambulatory chronic heart failure, J Card Fail, 26, 112, 10.1016/j.cardfail.2019.09.010 · DOI · Paper page
  16. El Hajj, 2021, Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction, J Am Heart Assoc, 10, 10.1161/JAHA.121.022930 · DOI · Paper page
  17. Li, 2006, Sex differences in the relationships between BMI, WHR and incidence of cardiovascular disease: a population-based cohort study, Int J Obes, 30, 1775, 10.1038/sj.ijo.0803339 · DOI

Cited by

See all 154

Metadata

Authors
Adamson, C., Kondo, T., Jhund, P. S., de Boer, R. A., Cabrera Honorio, J. W., Claggett, B., Desai, A. S., Alcocer Gamba, M. A., Al Habeeb, W., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Langkilde, A. M., Lindholm, D., Bachus, E., Litwin, S. E., Martinez, F., Petersson, M., Shah, S. J., Vaduganathan, M., Nguyen Vinh, P., Wilderäng, U., Solomon, S. D., & McMurray, J. J. V.
Venue
European Heart Journal
Published
2022-08-27
Volume
43
Issue
41
Pages
4406-4417
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4293332167
Cited by
154
References
16
FWCI
21.18
Type
journal article
Language
en
Open access
hybrid
Funders
  • AstraZeneca
  • British Heart Foundation (RE/18/6/34217)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin for heart failure according to body mass index: the DELIVER trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehac481
The paper
Adamson, C., Kondo, T., Jhund, P. S., de Boer, R. A., Cabrera Honorio, J. W., Claggett, B., Desai, A. S., Alcocer Gamba, M. A., Al Habeeb, W., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Langkilde, A. M., Lindholm, D., Bachus, E., Litwin, S. E., Martinez, F., Petersson, M., . . . McMurray, J. J. V. (2022). Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac481

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.